EBT Medical, Inc., a Toronto, Canada-based clinical-stage startup developing neuromodulation therapies for pelvic health disorders, secured USD $10m in Series A funding.
The round was co-led by SV Health Investors and Genesys Capital.<
The company intends to use the funds to:
– further develop its noninvasive neuromodulation technology,
– to pursue additional clinical data validating its safety and effectiveness,
– to expand the management team and
– for general administrative purposes.
Founded in 2014 based on scientific discoveries made at the University of Toronto and led by Keith R. Carlton, CEO, EBT Medical develops novel neuromodulation technologies that restore control, dignity and independence to people suffering from pelvic floor disorders. Its first proposed product is a clinical-grade, noninvasive neurostimulator and associated ecosystem for treating overactive bladder (OAB).
The company has a significant patent portfolio encompassing multiple neuromodulation technologies, including issued patents on the Saphenous nerve for all pelvic health indications.